Corinne Jenkins
Stock Analyst at Goldman Sachs
(1.67)
# 3,248
Out of 4,944 analysts
56
Total ratings
43.59%
Success rate
-4.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corinne Jenkins
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GERN Geron | Reinstates: Sell | $1 | $1.43 | -30.07% | 4 | Jul 10, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $59 → $66 | $97.86 | -32.56% | 8 | Dec 5, 2024 | |
| TGTX TG Therapeutics | Maintains: Neutral | $20 → $22 | $27.87 | -21.06% | 8 | Nov 5, 2024 | |
| FULC Fulcrum Therapeutics | Upgrades: Buy | $6 → $15 | $6.84 | +119.30% | 2 | May 14, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $53 → $46 | $24.42 | +88.37% | 5 | May 13, 2024 | |
| ROIV Roivant Sciences | Maintains: Buy | $16 → $18 | $11.96 | +50.50% | 5 | Apr 3, 2024 | |
| ALT Altimmune | Reinstates: Neutral | $13 | $3.74 | +247.59% | 3 | Jan 24, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Sell | $25 → $28 | $36.67 | -23.64% | 7 | Jan 9, 2024 | |
| BTAI BioXcel Therapeutics | Maintains: Neutral | $192 → $64 | $5.60 | +1,042.86% | 6 | Aug 15, 2023 | |
| RAPT RAPT Therapeutics | Maintains: Buy | $216 → $184 | $10.70 | +1,619.63% | 2 | Mar 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $21 | $1.70 | +1,135.29% | 2 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $14 | $6.49 | +115.72% | 2 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $0.39 | +4,002.56% | 2 | Dec 15, 2021 |
Geron
Jul 10, 2025
Reinstates: Sell
Price Target: $1
Current: $1.43
Upside: -30.07%
Rhythm Pharmaceuticals
Dec 5, 2024
Maintains: Buy
Price Target: $59 → $66
Current: $97.86
Upside: -32.56%
TG Therapeutics
Nov 5, 2024
Maintains: Neutral
Price Target: $20 → $22
Current: $27.87
Upside: -21.06%
Fulcrum Therapeutics
May 14, 2024
Upgrades: Buy
Price Target: $6 → $15
Current: $6.84
Upside: +119.30%
IDEAYA Biosciences
May 13, 2024
Maintains: Buy
Price Target: $53 → $46
Current: $24.42
Upside: +88.37%
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $16 → $18
Current: $11.96
Upside: +50.50%
Altimmune
Jan 24, 2024
Reinstates: Neutral
Price Target: $13
Current: $3.74
Upside: +247.59%
Harmony Biosciences Holdings
Jan 9, 2024
Maintains: Sell
Price Target: $25 → $28
Current: $36.67
Upside: -23.64%
BioXcel Therapeutics
Aug 15, 2023
Maintains: Neutral
Price Target: $192 → $64
Current: $5.60
Upside: +1,042.86%
RAPT Therapeutics
Mar 15, 2023
Maintains: Buy
Price Target: $216 → $184
Current: $10.70
Upside: +1,619.63%
Mar 7, 2023
Maintains: Buy
Price Target: $25 → $21
Current: $1.70
Upside: +1,135.29%
Dec 20, 2022
Maintains: Buy
Price Target: $9 → $14
Current: $6.49
Upside: +115.72%
Dec 15, 2021
Initiates: Neutral
Price Target: $16
Current: $0.39
Upside: +4,002.56%